The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post hoc survival analysis as per treatment arm, pCR and biomarkers.
Guarneri, V., Dieci, M.V., Griguolo, G., Miglietta, F., Girardi, F., Bisagni, G., et al. (2021). Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. EUROPEAN JOURNAL OF CANCER, 153, 133-141 [10.1016/j.ejca.2021.05.018].
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial
Musolino, Antonino;
2021
Abstract
The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post hoc survival analysis as per treatment arm, pCR and biomarkers.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Guarneri.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale / Version Of Record
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
524.71 kB
Formato
Adobe PDF
|
524.71 kB | Adobe PDF | Visualizza/Apri |
|
ScienceDirect_files_07Jan2025_14-47-39.137.zip
accesso aperto
Tipo:
File Supplementare
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
37.42 kB
Formato
Zip File
|
37.42 kB | Zip File | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
